NCT05490316View on ClinicalTrials.gov

A Study of IBI353 (Orismilast) in Chinese Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

December 30, 2022

Conditions

Healthy Subjects

Interventions

DRUG

IBI353 (Orismilast)

dose 1 or dose 2

DRUG

placebo

placebo

Trial Locations (1)

200040

Huashan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY